These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 18953065)

  • 41. Evolution of the treatment of primary central nervous system lymphoma in a Regional Cancer Center of South India: Impact of high-dose methotrexate on treatment outcome.
    Rudresha AH; Chaudhuri T; Lakshmaiah KC; Babu G; Lokesh KN; Rajeev LK
    J Cancer Res Ther; 2020; 16(1):13-17. PubMed ID: 32362603
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma.
    Remick SC; McSharry JJ; Wolf BC; Blanchard CG; Eastman AY; Wagner H; Portuese E; Wighton T; Powell D; Pearce T
    J Clin Oncol; 1993 Sep; 11(9):1691-702. PubMed ID: 8355036
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CHOD/BVAM regimen plus radiotherapy in patients with primary CNS non-Hodgkin's lymphoma.
    Bessell EM; Graus F; López-Guillermo A; Villá S; Verger E; Petit J; Holland I; Byrne P
    Int J Radiat Oncol Biol Phys; 2001 Jun; 50(2):457-64. PubMed ID: 11380234
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
    Morris PG; Correa DD; Yahalom J; Raizer JJ; Schiff D; Grant B; Grimm S; Lai RK; Reiner AS; Panageas K; Karimi S; Curry R; Shah G; Abrey LE; DeAngelis LM; Omuro A
    J Clin Oncol; 2013 Nov; 31(31):3971-9. PubMed ID: 24101038
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
    Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R
    Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial.
    Medical Research Council Brain Tumor Working Party
    J Clin Oncol; 2001 Jan; 19(2):509-18. PubMed ID: 11208845
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial.
    Roth P; Martus P; Kiewe P; Möhle R; Klasen H; Rauch M; Röth A; Kaun S; Thiel E; Korfel A; Weller M
    Neurology; 2012 Aug; 79(9):890-6. PubMed ID: 22895585
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initial chemotherapy in gliomatosis cerebri.
    Sanson M; Cartalat-Carel S; Taillibert S; Napolitano M; Djafari L; Cougnard J; Gervais H; Laigle F; Carpentier A; Mokhtari K; Taillandier L; Chinot O; Duffau H; Honnorat J; Hoang-Xuan K; Delattre JY;
    Neurology; 2004 Jul; 63(2):270-5. PubMed ID: 15277619
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Early response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response.
    Kim YR; Kim SH; Chang JH; Suh CO; Kim SJ; Kim Y; Hwang DY; Jang JE; Hyun SY; Cheong JW; Min YH; Kim JS
    Ann Hematol; 2014 Feb; 93(2):211-9. PubMed ID: 23903866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Primary central nervous system lymphoma: monocenter, long-term, intent-to-treat analysis.
    Kiewe P; Fischer L; Martus P; Thiel E; Korfel A
    Cancer; 2008 Apr; 112(8):1812-20. PubMed ID: 18318432
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A prospective phase II trial of response adapted whole brain radiotherapy after high dose methotrexate based chemotherapy in patients with newly diagnosed primary central nervous system lymphoma-analysis of acute toxicity profile and early clinical outcome.
    Adhikari N; Biswas A; Gogia A; Sahoo RK; Garg A; Nehra A; Sharma MC; Bhasker S; Singh M; Sreenivas V; Chawla R; Joshi G; Kumar L; Chander S
    J Neurooncol; 2018 Aug; 139(1):153-166. PubMed ID: 29633112
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-dose methotrexate based chemotherapy with deferred radiation for treatment of newly diagnosed primary central nervous system lymphoma.
    Gerard LM; Imrie KR; Mangel J; Buckstein R; Doherty M; Mackenzie R; Cheung MC
    Leuk Lymphoma; 2011 Oct; 52(10):1882-90. PubMed ID: 21663504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
    Qian L; Zhou C; Shen J; Cen J; Yin W
    Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Non-deep-seated primary CNS lymphoma: therapeutic responses and a molecular signature.
    Iwadate Y; Suganami A; Ikegami S; Shinozaki N; Matsutani T; Tamura Y; Saeki N; Yamanaka R
    J Neurooncol; 2014 Apr; 117(2):261-8. PubMed ID: 24488444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.
    Korfel A; Martus P; Nowrousian MR; Hossfeld DK; Kirchen H; Brücher J; Stelljes M; Birkmann J; Peschel C; Pasold R; Fischer L; Jahnke K; Thiel E;
    Br J Haematol; 2005 Jan; 128(2):177-83. PubMed ID: 15638851
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
    Yu J; Du H; Ye X; Zhang L; Xiao H
    Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.
    Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T; Fukushima T
    J Neurooncol; 2003 May; 63(1):87-95. PubMed ID: 12814260
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma.
    Blasco H; Senecal D; Le Gouge A; Pinard E; Benz-de Bretagne I; Colombat P; Hulot JS; Chatelut E; Le Guellec C
    Br J Clin Pharmacol; 2010 Sep; 70(3):367-75. PubMed ID: 20716237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
    Arellano-Rodrigo E; López-Guillermo A; Bessell EM; Nomdedeu B; Montserrat E; Graus F
    Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.